Stem Cell Therapeutics Corp., a Toronto-based life sciences company developing stem cell-related technologies, has completed its previously-announced merger with Trillium Therapeutics Inc. Shareholders of Toronto’s Trillium, a specialist in immunotherapy and cancer stem cell research, voted for the deal, which provides them with cash and shares in the new company. Trillium has been backed by Canadian venture capital firms since 1997.
STEM CELL THERAPEUTICS COMPLETES TRILLIUM MERGER AND ISSUES STOCK OPTIONS
Toronto, Canada, April 9, 2013 – Stem Cell Therapeutics Corp. (TSX-V:SSS) (“SCT”), a life sciences company developing stem cell-related technologies, today announced that it has completed its merger with Trillium Therapeutics Inc. (“Trillium”) previously announced on February 4, 2013. The shareholders of Trillium voted overwhelmingly to support the merger.
The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange.
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. (TSX-V: SSS) develops stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. SCT’s objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products. The Corporation’s intended corporate acquisitions and licensed acquisitions are positioning it principally in the field of cancer stem cell therapeutic development. SCT is a member of the Centre for Commercialization of Regenerative Medicine consortium.
For more information, visit: www.stemcellthera.com
Forward Looking Statements
This press release may contain forward-looking statements, which reflect SCT’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the satisfaction of the conditions precedent to the exercise of the option to acquire a license to certain technologies owned by University Health Network; the exercise of the option to acquire a license to certain technologies owned by University Health Network; the execution and delivery of a definitive license agreement with University Health Network if SCT determines to exercise the University Health Network option; changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT’s
ongoing quarterly and annual reporting, including in the base shelf prospectus dated March 1, 2011 and any prospectus supplement. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Chief Executive Officer
Stem Cell Therapeutics Corp.
+1 416 595 0627
Photo courtesy of Shutterstock.